MarketCap
Facebook
X
TelegramAnnual report 2024
added 01-24-2026
AstraZeneca PLC Revenue 2011-2026 | AZN
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue AstraZeneca PLC
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 54.1 B | 45.8 B | 44.4 B | 37.4 B | 26.6 B | 24.4 B | 22.1 B | 22.5 B | 23 B | 24.7 B | 26.1 B | 25.7 B | 28 B | 33.6 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 54.1 B | 22.1 B | 31.3 B |
Quarterly Revenue AstraZeneca PLC
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 8.22 B | - | - | - | 6.28 B | - | - | - | 5.82 B | - | - | - | 5.16 B | - | - | - | 5.05 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.22 B | 5.05 B | 6.1 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
Adagene
ADAG
|
10.2 M | $ 2.62 | 28.82 % | $ 147 M |  China |
 |
GlaxoSmithKline plc
GSK
|
31.4 B | $ 48.98 | 0.68 % | $ 173 B |  Britain |
 |
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K |  USA |
 |
Alterity Therapeutics Limited
ATHE
|
109 K | $ 3.51 | 7.34 % | $ 8.45 B |  Australia |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
Grifols, S.A.
GRFS
|
7.21 B | $ 9.25 | 1.49 % | $ 6.83 B |  Spain |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
Galapagos NV
GLPG
|
276 M | $ 34.61 | 0.61 % | $ 2.69 B |  Belgium |
 |
BioLineRx Ltd.
BLRX
|
28.9 M | $ 3.1 | 4.49 % | $ 908 M |  Israel |
 |
Zoetis
ZTS
|
9.26 B | $ 123.99 | -0.31 % | $ 56.3 B | USA |
 |
BioNTech SE
BNTX
|
482 M | $ 116.27 | -1.86 % | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
364 M | $ 235.41 | 2.95 % | $ 5 B |  Danmark |
 |
Burford Capital Limited
BUR
|
330 M | $ 9.74 | -1.37 % | $ 1.55 B | Britain |
 |
Acasti Pharma
ACST
|
100 M | - | 4.01 % | $ 150 M |  Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
829 M | $ 67.49 | -3.02 % | $ 9.03 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
853 K | $ 4.51 | 8.41 % | $ 9.81 B | Israel |
 |
Aeterna Zentaris
AEZS
|
9.59 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
142 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
60.3 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
732 M | $ 25.92 | -0.86 % | $ 1.26 B | USA |
 |
Amneal Pharmaceuticals
AMRX
|
2.79 B | $ 13.49 | -0.66 % | $ 4.17 B | USA |
 |
AIkido Pharma
AIKI
|
18.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
1.26 M | - | 2.71 % | $ 14 M | USA |
 |
Aravive
ARAV
|
9.14 M | - | -13.39 % | $ 1.45 M | USA |
 |
Alpine Immune Sciences
ALPN
|
30.1 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
1.16 M | - | -11.43 % | $ 502 K | USA |
 |
Ayala Pharmaceuticals
AYLA
|
692 K | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
66.4 M | $ 2.66 | -1.85 % | $ 16.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
54 K | - | -6.81 % | $ 3.04 B | USA |
 |
Brickell Biotech
BBI
|
8.01 M | - | -5.38 % | $ 6.06 M | USA |
 |
Athersys
ATHX
|
5.51 M | - | 3.77 % | $ 22.4 M | USA |
 |
BeiGene, Ltd.
BGNE
|
3.81 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biogen
BIIB
|
9.68 B | $ 171.89 | -1.1 % | $ 25 B | USA |